Data as of Dec 19
| -0.005 / -0.03%|
The 6 analysts offering 12-month price forecasts for Theravance Inc have a median target of 17.50, with a high estimate of 47.00 and a low estimate of 7.00. The median estimate represents a +14.98% increase from the last price of 15.22.
The current consensus among 7 polled investment analysts is to Hold stock in Theravance Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.